Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05102578Not ApplicableCompleted

Understanding Persistent Pain Using a Decision Aid Tool in a Scottish Pharmacy Setting.

Role: collaborator

NCT05476705Unknown

Identifying Drug-related Problems at ED Triage (DRP-EDiT) V1

Role: collaborator

NCT03920566Unknown

The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs

Role: collaborator

All 3 trials loaded